Cour Pharmaceutical Development Co. Inc.
http://www.courpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cour Pharmaceutical Development Co. Inc.
Takeda Acquires Celiac Venture PvP For Up To $330m
Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.
Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
Asia Deal Watch: Qpex Partners Its Experimental Antibiotics With Brii In Greater China
Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.
Takeda Adds Celiac Disease Candidate To GI Efforts
Takeda has exercised an option on partner Cour Pharmaceutical’s first-in-class lead product, after a positive Phase IIa study showed, for the first time, it was possible to induce specific immune tolerance to a foreign antigen in an autoimmune disease.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Nanotechnology, Chips, etc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice